Pharmaceuticals
Kangpu Biopharmaceuticals Received CDE Approval for Phase IIb Clinical Trial of KPG-818 in Moderate to Severe Cutaneous Manifestations of SLE
HEFEI, China, April 28, 2025 /PRNewswire/ -- Kangpu Biopharmaceuticals, Ltd. announced today that the Center for Drug Evaluation (CDE) ofChina's National Medical Products Administration (NMPA) has approved Phase IIb clinical trial of KPG-818 capsule for the treatment of moderate to severe cutaneo...
2025-04-28 20:00
1652
Celltrion to present six abstracts in inflammatory bowel disease (IBD) at 2025 Digestive Disease Week® (DDW)
* Six abstracts accepted for presentation includes post hoc analyses and real-world evidence for ZYMFENTRA® (infliximab-dyyb) * Findings reinforce clinical decision-making in long-term management of moderate-to-severe Crohn's disease and ulcerative colitis and underscore Celltrion's commitmen...
2025-04-28 20:00
2506
Comac Medical Announces New Leadership Appointments and International Expansion
Leadership transition and strategic growth initiatives mark the next phase of Comac Medical's development under EdgeCap Partners. SOFIA, Bulgaria, April 28, 2025 /PRNewswire/ -- Comac Medical, a leading full-service Contract Research Organization (CRO) in Central and Eastern Europe, announced t...
2025-04-28 16:00
2100
YolTech Announces First Clinical Data from Ongoing Investigator-Initiated Trial of YOLT-101, An In-Vivo Base Editing Therapy for Familial Hypercholesterolemia
SHANGHAI, April 28, 2025 /PRNewswire/ -- YolTech Therapeutics Co.,Ltd, a clinical-stage in vivo gene editing company committed to pioneering the next generation of precision genetic medicines, announced promising interim clinical data from an investigator-initiated trial (IIT) of YOLT-101 (NCT064...
2025-04-28 13:22
2200
2025 AACR | Abbisko Therapeutics Presents Late-Breaking Pre-clinical Research Results on ABSK112 (EGFR exon20ins), ABSK131 (PRMT5*MTA), and ABK-KRAS-1
SHANGHAI, April 27, 2025 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (Abbisko Therapeutics 02256.HK) today announced that it has presented four late-breaking pre-clinical research posters at the 2025 AACR conference held in Chicago, Illinois (USA) from April 25 to April 30. Results were shared ...
2025-04-28 10:00
2179
ImmVira Presented Clinical Results of Oncolytic Product MVR-C5252 Targeting Malignant Glioma via Convection-Enhanced Delivery at 2025 AACR Annual Meeting
SUZHOU, China, April 27, 2025 /PRNewswire/ -- From April 25 to April 30, 2025, U.S. time, ImmVira presented the Phase I clinical results of its oncolytic Herpes Simplex Virus ("oHSV") product MVR-C5252 targeting malignant glioma through poster presentation at American Association for Cancer Resea...
2025-04-28 09:00
2218
2025 AACR | Innovent Presents Preclinical Data of Multiple Novel Molecules including Bispecific and Tri-specific Antibodies and Bispecific ADCs
SAN FRANCISCO and SUZHOU, China, April 28, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmun...
2025-04-28 08:00
1608
Nona Biosciences' Partner Pfizer Presents Preclinical Data on TOP1i-Based ADC Targeting MSLN at AACR Annual Meeting 2025
CAMBRIDGE, Mass., April 27, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to I TM), today announced that its partner, Pfizer, has presented preclinical data on PF-08052666 (HBM9033; SGN-MesoC2), a first-in-class topoisome...
2025-04-28 08:00
1979
Everest Medicines Announces the "B" Marker Removal from Company's Stock Code, Effective May 2, 2025
SHANGHAI, April 28, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the "B" marker will cease to be...
2025-04-28 07:30
1995
ONO PHARMA USA Announces 2025 Golden Ticket CompetitionNow Accepting Applications from Innovative Startups
Ono Partnering with LabCentral and MBC BioLabs for Fifth Consecutive Year CAMBRIDGE, Mass., April 26, 2025 /PRNewswire/ -- ONO PHARMA USA today announced partnerships with LabCentral inCambridge, Mass., and MBC BioLabs in San Francisco and San Carlos, CA to award each organization one Golden Tick...
2025-04-27 00:00
2564
Antengene Presents Four Posters at AACR 2025 Highlighting Focuses on AnTenGagerTM TCEs and Synthetic Lethality
SHANGHAI and HONG KONG, April 26, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hem...
2025-04-26 08:30
3660
Innovent Announces NMPA Approval of Limertinib, a Third-generation EGFR TKI Collaborated with ASK Pharma, for the First-line Treatment of Lung Cancer
SAN FRANCISCO and SUZHOU,China, April 26, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metaboli...
2025-04-26 08:00
5303
Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Solid Tumors
CHENGDU, China, April 25, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced CM518D1, a CDH17-targeted antibody-drug conjugate (ADC) developed by Keymed, received Investigational New Drug (IND) approval from the Center for Drug Evaluation (CDE) ...
2025-04-25 17:44
2100
Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Gastrointestinal Cancers
CHENGDU, China, April 24, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") recently announced CM518D1, a CDH17-targeted antibody-drug conjugate (ADC) developed by Keymed, received Investigational New Drug (IND) approval from the Center for Drug Evaluation (CD...
2025-04-25 11:37
2289
Primo's Taoyuan Facility Achieves PIC/S GMP Certification, Paving the Way for Global Expansion in Nuclear Medicine.
TAIPEI, April 24, 2025 /PRNewswire/ -- Primo Biotechnology Co., Ltd. ("Primo") proudly announces that its Taoyuan pharmaceutical facility has successfully passed inspection by Taiwan Food and Drug Administration (TFDA) and has been award dual certification for PIC/S GMP and GDP. This achievement ...
2025-04-24 23:00
2401
Mabwell to Present Clinical Data of 9MW2821 Combined with Toripalimab in Patients with UC in an Oral Presentation at 2025 ASCO
SHANGHAI, April 24, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with an entire industry chain, announced that thePhase Ib/II clinical study results of the novel Nectin-4-targeting ADC 9MW2821 combined with toripalimab in patients with locally advanced...
2025-04-24 20:00
2257
Dizal to Showcase Data in Hematologic Malignancies and Lung Cancer at ASCO 2025
* DZD8586 study results in B-cell non-Hodgkin lymphomas (B-NHLs) were selected for oral and poster presentations. The analysis in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after covalent or non-covalent BTK inhibitors and BTK degraders was selected for oral presentation ...
2025-04-24 18:38
2298
Sun Pharma and Moebius Medical Announce Dual Publications on MM-II's Phase 2b Clinical Trial Results and Mechanism of Action in Osteoarthritis and Cartilage
- Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA models featured in two peer-reviewed articles - - New data on MM-II to be presented this weekend at the OARSI 2025 World Conference on Osteoarthritis - - MM-II recently granted Fast Track Designation ...
2025-04-24 14:31
2207
Kelun-Biotech to Present Results of Six Clinical Studies at 2025 ASCO Annual Meeting
CHENGDU, China, April 24, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) announced that it will present results from six Kelun-led clinical studies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held inChicago from May 30 to June 3. Resu...
2025-04-24 13:17
2250
Antengene to Present Latest Results From Two Clinical Studies at ASCO 2025
SHANGHAI and HONG KONG, April 24, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hem...
2025-04-24 10:26
2373
Week's Top Stories
Most Reposted
Amorepacific Showcases Innovative Technologies at CES 2026
[Picked up by 291 media titles]
2026-01-05 12:14
Radisson Hotel Group Revives Bangkok Icon with Opening of Radisson Hotel Chateau de Bangkok
[Picked up by 283 media titles]
2026-01-06 10:45
Panduit Announces Key Executive Appointments to Support Strategic Growth and Innovation
[Picked up by 281 media titles]
2026-01-07 10:00
iQIYI LAND Yangzhou to Open on February 8, Marking New Chapter in China's Immersive Entertainment Scene
[Picked up by 280 media titles]
2026-01-01 10:00
Space Summit 2026 to Convene Global Leaders in Singapore to Address the Growing Space Economy
[Picked up by 271 media titles]
2026-01-07 15:27Most Read
China Daily Launches "China Bound" -- An English-Language Smart-Tourism Service Platform for International Travelers
2026-01-01 17:04
8773
iQIYI LAND Yangzhou to Open on February 8, Marking New Chapter in China's Immersive Entertainment Scene
2026-01-01 10:00
7979
Domestic GPU Leader Biren Technology Listed on Hong Kong Stock Exchange
2026-01-02 17:41
7323
